CMMB - Chemomab Therapeutics Ltd.

1.83
-0.080   -4.372%

Share volume: 34,481
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.28%

PREVIOUS CLOSE
CHG
CHG%
$1.91
-0.08
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
6%
Profitability 0%
Dept financing 6%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.63%
1 Month
19.58%
3 Months
-33.21%
6 Months
-39.90%
1 Year
23.65%
2 Year
157.64%
Key data
Stock price
$1.83
P/E Ratio 
0.00
DAY RANGE
$1.75 - $1.99
EPS 
$0.04
52 WEEK RANGE
$0.83 - $3.86
52 WEEK CHANGE
$46.40
MARKET CAP 
1.127 M
YIELD 
N/A
SHARES OUTSTANDING 
14.219 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
1.16
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$108,157
AVERAGE 30 VOLUME 
$112,034
Company detail
CEO: Dale R. Pfost
Region: US
Website: chemomab.com
Employees: 20
IPO year: 2019
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Chemomab Therapeutics Ltd. discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24.

Recent news